ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Update

ALX Oncology Holdings Inc. (NASDAQ:ALXO) saw a significant decrease in short interest during the month of December. As of December 31st, there was short interest totalling 7,600,000 shares, a decrease of 9.4% from the December 15th total of 8,390,000 shares. Approximately 24.6% of the shares of the stock are short sold. Based on an average daily volume of 984,300 shares, the short-interest ratio is presently 7.7 days.

Insider Buying and Selling

In other news, Director Rekha Hemrajani bought 30,000 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was bought at an average price of $1.55 per share, for a total transaction of $46,500.00. Following the transaction, the director now directly owns 33,000 shares of the company’s stock, valued at $51,150. This represents a 1,000.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Over the last three months, insiders have sold 14,443 shares of company stock worth $23,309. Insiders own 33.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ALXO. Rhumbline Advisers boosted its position in shares of ALX Oncology by 10.8% during the second quarter. Rhumbline Advisers now owns 55,220 shares of the company’s stock valued at $333,000 after purchasing an additional 5,360 shares in the last quarter. AQR Capital Management LLC lifted its position in ALX Oncology by 50.7% during the second quarter. AQR Capital Management LLC now owns 18,079 shares of the company’s stock valued at $109,000 after buying an additional 6,080 shares during the period. SG Americas Securities LLC grew its position in shares of ALX Oncology by 33.6% in the 3rd quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock worth $50,000 after buying an additional 6,888 shares during the period. Hsbc Holdings PLC purchased a new position in ALX Oncology during the 2nd quarter valued at about $63,000. Finally, Wellington Management Group LLP boosted its stake in ALX Oncology by 15.2% during the third quarter. Wellington Management Group LLP now owns 167,831 shares of the company’s stock worth $305,000 after acquiring an additional 22,114 shares in the last quarter. Hedge funds and other institutional investors own 97.97% of the company’s stock.

ALX Oncology Trading Up 6.7 %

Shares of NASDAQ ALXO traded up $0.11 during midday trading on Friday, hitting $1.74. 578,695 shares of the company traded hands, compared to its average volume of 1,044,459. ALX Oncology has a 12-month low of $1.19 and a 12-month high of $17.83. The firm has a market cap of $91.77 million, a P/E ratio of -0.58 and a beta of 0.98. The stock has a 50-day moving average price of $1.59 and a 200 day moving average price of $2.51. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82.

Analyst Ratings Changes

A number of brokerages have recently weighed in on ALXO. HC Wainwright restated a “buy” rating and issued a $25.00 price objective on shares of ALX Oncology in a report on Wednesday, December 18th. Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a report on Wednesday, December 18th. Finally, Jefferies Financial Group cut ALX Oncology from a “buy” rating to a “hold” rating and dropped their target price for the company from $12.00 to $2.00 in a report on Thursday, December 19th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $8.50.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.